Femasys
Femasys is engaged in R&D and manufacture of medical devices for women's healthcare.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $8.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 14 % | 2 % | (11 %) | 52 % | 125 % | 121 % | 283 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (587 %) | (896 %) | (1229 %) | (1002 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (639 %) | (945 %) | (1329 %) | (1155 %) | (489 %) | (270 %) | (55 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 346 % | 482 % | 672 % | 504 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Femasys is a biomedical company that develops and commercializes non-surgical, minimally-invasive, and in-office solutions for women's health.
The company's product portfolio includes FemBloc for permanent birth control and FemVue for infertility diagnosis. These products are designed to be safer, more accessible, and more cost-effective than traditional surgical procedures. Femasys aims to address a significant unmet need in the women's health market by providing solutions that can be administered in a physician's office, reducing the need for hospitalization and general anesthesia.
The company's business model is focused on the development and commercialization of its proprietary technologies. Femasys generates revenue through the sale of its products to physicians and healthcare providers. The target market for Femasys' products includes gynecologists, obstetricians, and other healthcare professionals who specialize in women's health.
Keywords: women's health, biomedical, medical devices, non-surgical, minimally-invasive, in-office procedures, permanent birth control, infertility diagnosis, gynecologists, healthcare providers